Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Development stage||Note|
|08/27/18||GEM036||Hematopoietic stem cell fucosylation||Prevention of infection & GvHD from hematopoietic stem cell transplantation||see Note||Phase 3 ready with FDA SPA||In Phase II study:
Statistically significant acceleration of immune system reconstitution
Significantly reduced infection and GvHD
Positioned to be best-in-classNo
reports of adverse event specifically attributable to fucosylation
|08/07/18||GEM035||An anti-ENO1 antibody||Immune diseases, various cancers||SC||Preclinical （close to IND）||Showed efficacy in animal models of multiple sclerosis, RA, pancreatic cancer and liver cancer.
Also applicable to IBD and COPD etc.
Completed pre-clinical studies including monkey toxicity studies, GMP production.
|08/07/18||GEM034||Derivative of neuroprotective protein||Stroke, Huntington chorea, Schizophrenia and PTSD||IV||Preclinical||A cell-permeable recombinant peptide.
Can cross the blood-brain barrier, is resistant to degradation, and can bind constitutively to its substrates.
Significantly reduces brain damage in rodent stroke model.
Expected to be treated after stroke without diagnosis of stroke type before dosing.
|08/07/18||GEM033||Inhibitors of bacterial resistance mechanisms||Gram-negative MDR bacterial infections, lung infections in cystic fibrosis （CF） patients||see Note||Preclinical||Restore effectiveness of shelved antibiotics.
Lower the effective dose of antibiotics.
Mitigate antibiotic resistance.
Disrupt biofilm-based infections.
Over 1,000 compounds with lead compounds for each indication identified.
Route : Intravenous, Aerosol, Topical
|07/26/18||GEM032||Calcium release-activated calcium channel inhibitor||Respiratory & immuno-inflammatory diseases||Oral||Phase 1||- Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation.
- Phase 1 SAD/MAD study were completed.
|07/26/18||GEM031||Calcium release-activated calcium channel inhibitor||Lymphomas & Solid cancer||Oral||Phase 1||- Demonstrated preclinical activity in a broad range of cancers.
- Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing.
|07/26/18||GEM030||PI3K δ/γ dual inhibitor||Hematological malignancies, T cell Lymphoma, Hodgkin Lymphoma||Oral||Phase 2||- Highly specific dual PI3K δ/γ inhibitor with nano‐molar inhibitory potency
- Single-agent and combination with immune checkpoint inhibitor programs
- Inhibits primary patient leukemic/lymphoma cells
- Dose escalation study demonstrated an acceptable safety and tolerability with promising clinical activity
|07/20/18||GEM029||A cancer stem cell-associated transcription factor inhibitor||Malignant gliomas including glioblastoma （GBM）||Oral||Phase 1 ready||-Directly kills the cancer stem cells.
-Significantly improves survival in orthotopic GBM PDX models.
-Inhibits tumor growth in a mouse implanted with GBM cells and the growth inhibition is augmented by combination with temozolomide/radiation.
-No significant toxicities are identified at therapeutic doses.
|07/09/18||GEM028||miRNA targeting refractory colon cancer with mutated K-ras and refractory pancreatic cancer||pancreatic cancer colon cancer||IV||Preclinical||The miRNA regulates K-ras, Bcl2, survivin, and NF-kB and demonstrate excellent antitumor effect in vitro and in vivo.||Contact|
|07/09/18||GEM027||miRNA targeting refractory colon cancer with mutated K-ras||colon cancer||IV||Preclinical||The miRNA regulates EGFR signaling pathway by directly inhibiting of both KRAS and AKT1 and demonstrate excellent antitumor effect in vitro and in vivo.||Contact|